Treatment strategy for de novo metastatic nasopharyngeal carcinoma: a literature review

被引:2
作者
Liu, Qin [1 ]
Li, Jishi [2 ]
Ng, Wai Tong [1 ,2 ]
Lee, Anne W. M. [2 ,3 ,4 ]
机构
[1] Univ Hong Kong, Li Ka Shing Fac Med, Dept Clin Oncol, Hong Kong, Peoples R China
[2] Univ Hong Kong, Shenzhen Hosp, Dept Clin Oncol, Shenzhen Key Lab Metastasis & Personalized Therapy, Shenzhen 518053, Peoples R China
[3] Univ Hong Kong, Clin Oncol Ctr, Shenzhen Hosp, Shenzhen, Peoples R China
[4] Univ Hong Kong, Shenzhen Hosp, Dept Clin Oncol, Shenzhen Key Lab Canc Metastasis & Personalized Th, 1,Haiyuan 1st Rd, Shenzhen 518053, Peoples R China
关键词
Metastatic nasopharyngeal carcinoma; radiation therapy; chemotherapy; immunotherapy; PHASE-II TRIAL; PLASMA EBV DNA; LOCOREGIONAL RADIOTHERAPY; STAGING SYSTEM; M1; STAGE; RECURRENT; SURVIVAL; CHEMOTHERAPY; GEMCITABINE; CISPLATIN;
D O I
10.21037/cco-23-32
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and Objective: Nasopharyngeal carcinoma (NPC) with de novo distant metastasis (M1) is classified as stage IVB in the 8th edition of the staging system jointly adopted by the American Joint Committee on Cancer and the International Union against Cancer Control. Patients with M1 disease generally have a relatively short life expectancy. This review discusses the personalized and intensified treatment strategies for de novo metastatic NPC. Methods: A literature search was conducted on PubMed to identify peer-reviewed publications on subdivisions of M1 disease and treatment of de novo metastatic NPC. Clinicaltrials.gov and Chinese Clinical Trial Register were searched to identify ongoing clinical trials evaluating systemic or local therapy of previously untreated metastatic NPC.Key Content and Findings: M1 encompasses a diverse group of diseases. Several important factors, including tumor burden, EBV-DNA levels, location of involvement, the number of metastasis, and treatment strategies, influence the prognosis of NPC patients. Researchers have attempted to define M1 subcategorization to reflect the underlying risk profile and tailor personalized treatment. Recent advancements have brought new hope for this otherwise incurable condition. In the era of immunotherapy, checkpoint inhibitors have become the first-line systemic treatment for metastatic NPC in JUPITER-02, CAPTAIN-1st, and RATIONALE-309. Additionally, the value of radical locoregional radiation therapy and ablative treatment to distant metastatic sites should not be overlooked in patients with de novo metastatic diseases. Locoregional radiation with concurrent chemotherapy, maintenance chemotherapy, and radical local treatment to metastatic sites are emerging as potential treatment options. Conclusions: Given the diversity of metastatic NPC, a multimodality approach incorporating chemotherapy, immunotherapy, locoregional radiation and ablative treatment to metastatic sites has been shown to improve overall control. Further research is needed to determine the efficacy and optimal duration of maintenance therapy.
引用
收藏
页数:14
相关论文
共 66 条
[1]  
[Anonymous], 2022, NCCN treatment guidelines in oncology: head and neck cancers
[2]   Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature [J].
Ashworth, Allison ;
Rodrigues, George ;
Boldt, Gabriel ;
Palma, David .
LUNG CANCER, 2013, 82 (02) :197-203
[3]   Activity of paclitaxel by three-hour infusion in Asian patients with metastatic undifferentiated nasopharyngeal cancer [J].
Au, E ;
Tan, EH ;
Ang, PT .
ANNALS OF ONCOLOGY, 1998, 9 (03) :327-329
[4]   ESMO-EURACAN Clinical Practice Guideline update for nasopharyngeal carcinoma: adjuvant therapy and first-line treatment of recurrent/metastatic disease [J].
Bossi, P. ;
Chan, A. T. ;
Even, C. ;
Machiels, J. -P. .
ANNALS OF ONCOLOGY, 2023, 34 (03) :247-250
[5]   Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].
Bossi, P. ;
Chan, A. T. ;
Licitra, L. ;
Trama, A. ;
Orlandi, E. ;
Hui, E. P. ;
Halamkova, J. ;
Mattheis, S. ;
Baujat, B. ;
Hardillo, J. ;
Smeele, L. ;
van Herpen, C. ;
Castro, A. ;
Machiels, J-P .
ANNALS OF ONCOLOGY, 2021, 32 (04) :452-465
[6]   Surgical resection of pulmonary metastases from colorectal cancer: 11 years of experiences [J].
Cao, Guoquan ;
Cheng, Dezhi ;
Ye, Lechi ;
Pan, Yiyuan ;
Yang, Fan ;
Lyu, Shixu .
PLOS ONE, 2017, 12 (04)
[7]   Refining TNM-8 M1 categories with anatomic subgroups for previously untreated de novo metastatic nasopharyngeal carcinoma [J].
Chan, Sik Kwan ;
Lin, Cheng ;
Huang, Shao Hui ;
Chau, Tin Ching ;
Guo, Qiao Juan ;
O'Sullivan, Brian ;
Lam, Ka On ;
Chau, Sze Chun ;
Chan, Sum Yin ;
Tong, Chi Chung ;
Vardhanabhuti, Varut ;
Kwong, Dora Lai Wan ;
So, Tsz Him ;
Ng, Chor Yi ;
Leung, To Wai ;
Luk, Mai Yee ;
Lee, Anne Wing Mui ;
Choi, Horace Cheuk Wai ;
Pan, Jian Ji ;
Lee, Victor Ho Fun .
ORAL ONCOLOGY, 2022, 126
[8]   An Exploratory Study of Refining TNM-8 M1 Categories and Prognostic Subgroups Using Plasma EBV DNA for Previously Untreated De Novo Metastatic Nasopharyngeal Carcinoma [J].
Chan, Sik-Kwan ;
O'Sullivan, Brian ;
Huang, Shao Hui ;
Chau, Tin-Ching ;
Lam, Ka-On ;
Chan, Sum-Yin ;
Tong, Chi-Chung ;
Vardhanabhuti, Varut ;
Kwong, Dora Lai-Wan ;
Ng, Chor-Yi ;
Leung, To-Wai ;
Luk, Mai-Yee ;
Lee, Anne Wing-Mui ;
Choi, Horace Cheuk-Wai ;
Lee, Victor Ho-Fun .
CANCERS, 2022, 14 (08)
[9]   Defining a cohort of oligometastatic nasopharyngeal carcinoma patients with improved clinical outcomes [J].
Chee, Jeremy ;
Liu, Xuandao ;
Eu, Donovan ;
Loh, Thomas ;
Ho, Francis ;
Wong, Lea C. ;
Tham, Ivan ;
Tan, Chee S. ;
Goh, Boon C. ;
Lim, Chwee M. .
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2020, 42 (05) :945-954
[10]   Locoregional radiotherapy in patients with distant metastases of nasopharyngeal carcinoma at diagnosis [J].
Chen, Ming-Yuan ;
Jiang, Rou ;
Guo, Ling ;
Zou, Xiong ;
Liu, Qing ;
Sun, Rui ;
Qiu, Fang ;
Xia, Zhong-Jun ;
Huang, Hui-Qiang ;
Zhang, Li ;
Hong, Ming-Huang ;
Mai, Hai-Qiang ;
Qian, Chao-Nan .
CHINESE JOURNAL OF CANCER, 2013, 32 (11) :604-613